Three-drug combo targets immune suppression to overcome melanoma resistance

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...
Technology Networks

Three Drug Combination Enhances Immune Response to Melanoma

Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored ...
ascopubs.org

CD4 effector T cell expansion to identify objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX (mFFX) as first-line therapy for ...

A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers. Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for ...
BioWorld

BA-4415, an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy

Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...
Business Wire

Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, ...
ascopubs.org

Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.

Impact of microbiota specific circulating memory T cells in response to immunotherapy. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
Nasdaq

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...
The New England Journal of Medicine

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...